T-SPOT®.TB Gains FDA Premarket Approval
go back to news archivesThe FDA has approved a premarket approval application for the T-SPOT.TB test from Oxford Immunotec. The T-SPOT.TB test is a laboratory based cellular blood test that is intended for use as an aid in the diagnosis of Mycobacterium tuberculosis infection and disease. T-SPOT.TB improves accuracy and eliminates the logistical challenges found with the current tuberculin skin test. The T-SPOT.TB test has been tested in patient groups indicated for screening for TB infection according to current American Thoracic Society and Center for Disease Control Guidance; such as, HIV positive persons, recent contacts of TB case patients, patients with chronic renal failure, children, and immunosuppressed patients. T-SPOT.TB is the only blood test that has demonstrated in a pivotal clinical study both sensitivity and specificity exceeding ninety-five percent and reliability in all targeted patient groups. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Oxford Immunotec View Company Information
Posted on August 5, 2008
LATEST MICROBIOLOGY NEWS
-
PMM-Swab: the Safest Solution for Swab Sampling
21 May 2025 -
PowerLine: Fast, Accurate Milk Testing Solution
14 May 2025
MICROBIOLOGY EVENTS
-
Future Labs Live 2025
27 May 2025 -
Improve Your Productivity with Legionella pneumophila Rapid Testing
27 May 2025 -
Pharmig’s 18th Annual Irish Conference
28 May 2025 -
Common Mycotoxin Testing Errors and How to Address Them
28 May 2025 -
Driving Quality Goals Through Analytical Tools & Standardization
4 Jun 2025 -
2025 Endotoxin Testing Summit
10 Jun 2025 -
15th Annual Food Sure Summit
15 Jun 2025 -
WaterMicro25
15 Jun 2025 -
Pharmig Europe 2025
17 Jun 2025 -
ASM Microbe
19 Jun 2025